Search results
Results From The WOW.Com Content Network
OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.
Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
OPKO Health (OPK) witnesses sluggishness in the Products revenues segment in Q4. However, contribution from RAYALDEE has been significant in the quarter.
OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.
OPKO Health is a diversified healthcare company present in more than 30 countries. The company's primary businesses include [citation needed] Bioreference Laboratories, a clinical laboratory with a core genetic testing business; The 4K Test Score, a blood test for prostate cancer; Pharmaceutical development, with products such as Rayaldee
OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways ...
Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market trading hours, Opko stock was down 0.63% at the ...